Planta Med 2004; 70(11): 1033-1038
DOI: 10.1055/s-2004-832643
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Enhancement of Antitumor Effects of Paclitaxel (Taxol) in Combination with Red Ginseng Acidic Polysaccharide (RGAP)

Han Jae Shin1 , Young Sook Kim1 , Yi Seong Kwak1 , Yong Bum Song1 , Young Sang Kim2 , Jong Dae Park1
  • 1KT&G Central Research Institute, Daejeon, Korea
  • 2Department of Biochemistry, Chungnam National University, Daejeon, Korea
Further Information

Publication History

Received: February 23, 2004

Accepted: July 12, 2004

Publication Date:
18 November 2004 (online)

Abstract

We have recently reported that red ginseng acidic polysaccharide (RGAP), isolated from Korean red ginseng (Panax ginseng C. A. Meyer), shows immunomodulatory and antitumor activities, mainly mediated by the nitric oxide (NO) production of macrophages. This compound may be used in cancer therapy alone or in combination with other chemotherapeutic agents. The synergistic effect of RGAP and paclitaxel (taxol) was evaluated to develop new biological response modifiers in cancer therapy. The present study demonstrates a synergistic antitumor effect of RGAP and paclitaxel in mice transplanted with sarcoma 180 and B16 melanoma. Combined treatment with paclitaxel (5 or 15 mg/kg) and RGAP (25 mg/kg) resulted in a 28.6 or 42.8 % increase in the life span of ICR mice bearing sarcoma 180 tumor cells, while no obvious effect was seen on sole paclitaxel treatment. When a combination of paclitaxel (10 mg/kg) and RGAP (100 mg/kg) was administered to C57BL/6 mice implanted with B16 melanoma, the tumor weight per mouse also decreased by 76.3 %, suggesting that RGAP may be used as an adjuvant in medicinal applications of paclitaxel. The augmented antitumor effect of paclitaxel is supposed to be the result of the immunomodulating antitumor effect of RGAP. RGAP, having B cell specific mitogenic activity, induced the secretion of interleukin-6 (IL-6) in spleen cells in a concentration-dependent manner (5 to 500 μg/μL). RGAP also restored the proliferation of splenocytes and NK cell activity suppressed by paclitaxel. Flow cytometric analysis of splenocytes in mice treated with paclitaxel showed a significant increase of CD11b+ cells. Additionally, a synergistic effect of RGAP and paclitaxel was found to effect an increased tumoricidal activity of macrophages. The above results suggest that clinical trials of RGAP as an adjuvant in cancer chemotherapy of paclitaxel are highly feasible.

References

Dr. Jong-Dae Park

KT&G Central Research Institute

302 Shinsung-dong

Yuseong-gu

Daejeon

Seoul 305-345

Korea

Phone: +82-42-866-5534

Fax: +82-42-862-1949

Email: jdpark@ktng.com

    >